How to take Penpulimab

Penpulimab (Penpulimab), as a new PD-1 immune checkpoint inhibitor, has shown good efficacy in the fields of relapsed/refractory classical Hodgkin lymphoma (cHL) and recurrent or metastatic nasopharyngeal carcinoma (NPC). The administration of ampilimab is relatively simple, but the entire treatment process must be carried out under the strict supervision of medical professionals to ensure safety and efficacy. The drug is administered by intravenous infusion, which works by injecting the drug directly into the blood circulation system. Each infusion usually takes 30 to 60 minutes, and patients need to be closely observed during the infusion to detect and deal with possible adverse reactions in a timely manner.

In terms of dosing frequency, penpilimab is usually administered every two to three weeks. The specific time interval and dosage need to be adjusted based on the type of cancer the patient has, the degree of disease progression, and the individual's health condition. For example, when treating patients with Hodgkin's lymphoma or nasopharyngeal cancer, doctors develop a personalized dosing regimen based on clinical guidelines and the patient's tolerance. Regular laboratory testing and imaging evaluation are also essential throughout treatment to monitor disease response and promptly identify potential immune-related side effects.

The time to onset of efficacy of ampilimab varies among individuals. Some patients may be able to observe improvement in symptoms, such as tumor shrinkage or physical recovery, within a few weeks of starting treatment, but other patients may need several months of continued treatment to show significant effects. This delayed response is because immunotherapy works differently than traditional chemotherapy. Ampulimab does not directly kill cancer cells, but by relieving T cell inhibition and reactivating the immune system to fight tumors. Therefore, the onset of therapeutic effects may be gradual, but once an effective immune response is established, it can often lead to more durable and far-reaching disease control.

Reference materials:https://synapse.patsnap.com/article/what-is-penpulimab-used-for